The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey

被引:0
|
作者
Beltran-Bless, Ana-Alicia [1 ]
Larocque, Gail [2 ]
Brackstone, Muriel [3 ]
Arnaout, Angel [2 ,4 ]
Caudrelier, Jean-Michel [2 ,5 ]
Boone, Denise [2 ]
Fallah, Parvaneh [1 ]
Ng, Terry [1 ,2 ,6 ]
Cross, Peter [5 ]
Alqahtani, Nasser [1 ]
Hilton, John [1 ,2 ,6 ]
Vandermeer, Lisa [6 ]
Pond, Gregory [7 ]
Clemons, Mark [1 ,2 ,6 ]
机构
[1] Univ Ottawa, Dept Med, Div Med Oncol, Ottawa, ON, Canada
[2] Ottawa Hosp, Canc Ctr, Ottawa, ON, Canada
[3] London Hlth Sci Ctr, Dept Surg, London, ON, Canada
[4] Ottawa Hosp Canc Ctr, Dept Surg, Ottawa, ON, Canada
[5] Ottawa Hosp Canc Ctr, Dept Radiat Med, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON, Canada
[7] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
关键词
Breast cancer; Survivorship; Follow-up; Patient survey; CARE; TRIAL;
D O I
10.1007/s10549-023-07232-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Despite limited evidence supporting its effectiveness, most guidelines recommend long-term, routinely scheduled in-person surveillance of patients with early breast cancer (EBC). The COVID-19 pandemic led to increased use of virtual care. This survey evaluated patient perspectives on follow-up care.Methods Patients with EBC undergoing surveillance were surveyed about follow-up protocols, perceptions, and interest in clinical trials assessing different follow-up strategies.Results Of 402 approached patients 270 completed the survey (response rate 67%). Median age 62.5 years (range 25-86) and median time since breast cancer diagnosis was 3.8 years (range < 1-33 years). Most (n = 148/244, 60%) were followed by more than one provider. Routine follow-ups with breast examination were mostly conducted by medical/radiation oncologists every 6 months (n = 110/236, 46%) or annually (n = 106/236, 44%). Participants felt routine follow-up was useful to monitor for recurrence, manage side effects of cancer treatment and to provide support/reassurance. Most participants felt regular follow-up care would detect recurrent cancer earlier (n = 214/255, 96%) and increase survival (n = 218/249, 88%). The COVID-19 pandemic reduced the number of in-person visits for 54% of patients (n = 63/117). Patients were concerned this reduction of in-person visits would lead to later detection of both local (n = 29/63, 46%) and distant recurrences (n = 25/63, 40%). While many felt their medical and radiation oncologists were the most suited to provide follow-up care, 55% felt comfortable having their primary care provider (PCP) conduct surveillance. When presented with a scenario where follow-up has no effect on earlier detection or survival, 70% of patients still wanted routine in-person follow-up for reassurance (63%) with the goal of earlier recurrence detection (56%).Conclusions Despite limited evidence of effectiveness of routine in-person assessment, patients continue to place importance on regularly scheduled in-person follow-up.
引用
收藏
页码:531 / 538
页数:8
相关论文
共 50 条
  • [1] The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey
    Ana-Alicia Beltran-Bless
    Gail Larocque
    Muriel Brackstone
    Angel Arnaout
    Jean-Michel Caudrelier
    Denise Boone
    Parvaneh Fallah
    Terry Ng
    Peter Cross
    Nasser Alqahtani
    John Hilton
    Lisa Vandermeer
    Gregory Pond
    Mark Clemons
    Breast Cancer Research and Treatment, 2024, 204 : 531 - 538
  • [2] The Effects of COVID-19 Pandemic on the Follow-Up and Treatment Process of Gynecological Cancers and Breast Cancer
    Aydin Dogan, Reyhan
    Guducu, Neriman
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2021, 36 (01): : 133 - 138
  • [3] Breast Cancer Diagnosis, Treatment and Follow-Up During COVID-19 Pandemic
    Soran, Atilla
    Gimbel, Michael
    Diego, Emilia
    EUROPEAN JOURNAL OF BREAST HEALTH, 2020, 16 (02) : 86 - 88
  • [4] The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer
    Surujballi, Julian
    Shah, Hely
    Hutton, Brian
    Alzahrani, Mashari
    Beltran-Bless, Ana-Alicia
    Shorr, Risa
    Larocque, Gail
    McGee, Sharon
    Cole, Katherine
    Ibrahim, Mohammed F. K.
    Fernandes, Ricardo
    Arnaout, Angel
    Stober, Carol
    Liu, Michelle
    Sienkiewicz, Marta
    Saunders, Deanna
    Vandermeer, Lisa
    Clemons, Mark
    CANCER TREATMENT REVIEWS, 2021, 97
  • [5] Comparison and selection of patient follow-up systems for covid-19 pandemic patients
    Tamer Eren
    Tuğba Danışan
    Ayşegül Deringöz
    Güler Aksüt
    Fashion and Textiles, 9
  • [6] Comparison and selection of patient follow-up systems for covid-19 pandemic patients
    Eren, Tamer
    Danisan, Tugba
    Deringoz, Aysegul
    Aksut, Guler
    FASHION AND TEXTILES, 2022, 9 (01)
  • [7] Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers
    Beltran-Bless, A. -A.
    Larocque, G.
    Arnaout, A.
    Caudrelier, J. -M.
    Vandermeer, L.
    Pond, G.
    Clemons, M.
    BREAST, 2023, 68 : S132 - S132
  • [8] Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers
    Beltran-Bless, Ana-Alicia
    Larocque, Gail
    Arnaout, Angel
    Caudrelier, Jean-Michel
    Hilton, John
    Alqahtani, Nasser
    Vandermeer, Lisa
    Pond, Gregory
    Clemons, Mark
    SUPPORTIVE CARE IN CANCER, 2025, 33 (03)
  • [9] Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic
    Grandvuillemin, Aurelie
    Rocher, Fanny
    Valnet-Rabier, Marie Blanche
    Drici, Milou-Daniel
    French Pharmacovigilance Network
    THERAPIE, 2023, 78 (05): : 523 - 529
  • [10] A longitudinal follow-up study on the prognosis of patients with breast cancer with delayed diagnosis during the COVID-19 pandemic
    Yi, J. P.
    Baek, J. M.
    Kim, Y-S.
    Jeon, Y. W.
    Yoon, C. I.
    Rhu, J.
    Lim, S. H.
    Kang, Y-J.
    ANNALS OF ONCOLOGY, 2024, 35 : S345 - S345